Skip to main content
Premium Trial:

Request an Annual Quote

Gencove Wins $330K NIH Grant for Polygenic Risk Score Evaluation Tech

NEW YORK (GenomeWeb) — Gencove said today that it has received a $330,234 grant from the National Institutes of Health to validate its technologies for use in estimating polygenic risk scores.

New York City-based Gencove — a spinout of the New York Genome Center — offers low-coverage whole-genome sequencing and has developed imputation algorithms and informatics to extract useful information from the data.

With the Phase I Small Business Innovation Research grant, which runs from May through October, Gencove aims to validate its methods for calculating polygenic risk scores from low-pass sequencing data for population-scale screening applications, with an initial focus on coronary artery disease.

"The flexibility, operational efficiency, cost-effectiveness, and population-agnostic nature of low-pass sequencing make it a great choice for calculating polygenic risk scores at scale," Gencove CEO Joe Pickrell said in a statement.

Last month, Gencove closed a $3.2 million financing round.